54 reports of this reaction
1.5% of all CISATRACURIUM BESYLATE reports
#17 most reported adverse reaction
HYPERTHERMIA MALIGNANT is the #17 most commonly reported adverse reaction for CISATRACURIUM BESYLATE, manufactured by Fresenius Kabi USA, LLC. There are 54 FDA adverse event reports linking CISATRACURIUM BESYLATE to HYPERTHERMIA MALIGNANT. This represents approximately 1.5% of all 3,661 adverse event reports for this drug.
Patients taking CISATRACURIUM BESYLATE who experience hyperthermia malignant should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERTHERMIA MALIGNANT is a less commonly reported adverse event for CISATRACURIUM BESYLATE, but still significant enough to appear in the safety profile.
In addition to hyperthermia malignant, the following adverse reactions have been reported for CISATRACURIUM BESYLATE:
The following drugs have also been linked to hyperthermia malignant in FDA adverse event reports:
HYPERTHERMIA MALIGNANT has been reported as an adverse event in 54 FDA reports for CISATRACURIUM BESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERTHERMIA MALIGNANT accounts for approximately 1.5% of all adverse event reports for CISATRACURIUM BESYLATE, making it a notable side effect.
If you experience hyperthermia malignant while taking CISATRACURIUM BESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.